Think Surgical announced today that it entered into a debt facility with Symbiotic Capital worth up to $65 million in growth capital.
Fremont, California-based Think Surgical’s facility provided an initial funded tranche of $15 million. It also includes an additional $15 million based on the achievement of certain milestones, with up to $25 million in discretionary capital.
Think Surgical plans to use the proceeds to advance its dual-channel commercial strategy for the TMINI miniature robotic system.
“This facility, combined with recent additional investments by our existing investors, will allow us to continue our significant growth and development of TMINI, and is expected to fully finance the company to profitability,” said Stuart Simpson, president and CEO of Think Surgical.
TMINI originally got the FDA’s green light in May 2023. It features a wireless, robotic handpiece that assists surgeons in performing total knee replacement. Following a CT-based three-dimensional surgical plan, the TMINI robotic handpiece automatically compensates for the surgeon’s hand movement to locate bone pins along precisely defined planes. Cutting guides are then connected to the bone pins for accurate bone resection.
As of February 2026, TMINI works with nine different compatible options. Those include Zimmer Biomet’s Persona Knee and Stryker’s Triathlon implant, as well as implants from Maxx Orthopedics, Waldemar Link, Medacta and more.
“We are excited about TMINI’s potential to advance surgical robotics in the field of orthopedics, and we are impressed by the compelling value proposition it offers to both physicians and patients,” said Himani Bhalla, senior managing director and chief investment officer of Symbiotic Capital.
